LYTACs that engage the asialoglycoprotein receptor for targeted protein degradationGreen Ahn, Carolyn R. Bertozzi, Steven M. Banik et al.|Nature Chemical Biology|2021Cited by 579
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein DegradationGreen Ahn, Carolyn R. Bertozzi, Steven M. Banik et al.|ChemRxiv|2020Cited by 13
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast TumorsCaitlyn L. Miller, Ronald Levy|The Journal of Immunology|2023Cited by 3
Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein DegradationGreen Ahn, Carolyn R. Bertozzi, Caitlyn L. Miller et al.|ChemRxiv|2020Cited by 2